Taienkang announced that Shandong Huabo Kaisheng Biotechnology Co., Ltd., a wholly-owned subsidiary of the company, recently received the “Drug Registration Certificate” for laberolol hydrochloride tablets issued by the State Drug Administration. The registration classification is class 3 chemicals, with specifications of 0.1 g and 0.2 g. This drug is an alpha receptor and beta blocker. It is mainly used to treat various types of hypertension, and is currently the drug of choice for treating high blood pressure during pregnancy. This variety approved by Huabo Kaisheng is the second domestic laberol hydrochloride tablet to pass the consistency evaluation. There is uncertainty about future sales of this product.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.